![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Simpson, Eric L.; Blauvelt, Andrew; Silverberg, Jonathan I.; Cork, Michael J.; Katoh, Norito; Mark, Thomas; Schneider, Shannon K. R. und Wollenberg, Andreas 
ORCID: https://orcid.org/0000-0003-0177-8722
(2024):
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
In: American Journal of Clinical Dermatology, Bd. 25, Nr. 1: S. 139-148
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-0177-8722
(2024):
Tralokinumab Provides Clinically Meaningful Responses at Week 16 in Adults with Moderate-to-Severe Atopic Dermatitis Who Do Not Achieve IGA 0/1.
In: American Journal of Clinical Dermatology, Bd. 25, Nr. 1: S. 139-148
[PDF, 1MB]
Simpson, Eric L.; Pink, Andrew E.; Blauvelt, Andrew; Gooderham, Melinda; Armstrong, April W.; Worm, Margitta; Katoh, Norito; Peris, Ketty; Puig, Luis; Barbarot, Sébastien; Mark, Thomas; Steffensen, Louise Abildgaard; Tindberg, Ann-Marie und Wollenberg, Andreas ORCID: https://orcid.org/0000-0003-0177-8722
(2023):
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
In: American Journal of Clinical Dermatology, Bd. 24, Nr. 6: S. 939-952
[PDF, 2MB]
ORCID: https://orcid.org/0000-0003-0177-8722
(2023):
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
In: American Journal of Clinical Dermatology, Bd. 24, Nr. 6: S. 939-952
[PDF, 2MB]
Blauvelt, Andrew; Wollenberg, Andreas; Eichenfield, Lawrence F.; Zhang, Haixin; Sierka, Debra; Khokhar, Faisal A.; Vakil, Jignesh; Shabbir, Arsalan; Marco, Ainara Rodriguez und Cyr, Sonya L.
(2022):
No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
In: Advances in Therapy, Bd. 40, Nr. 1: S. 367-380
Blauvelt, Andrew; Langley, Richard G.; Lacour, Jean-Philippe; Toth, Darryl; Laquer, Vivian; Beissert, Stefan; Wollenberg, Andreas; Herranz, Pedro; Pink, Andrew E.; Peris, Ketty; Fangel, Stine; Gjerum, Le; Corriveau, Joshua; Saeki, Hidehisa; Warren, Richard B.; Simpson, Eric und Reich, Kristian
(2022):
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
In: Journal of the American Academy of Dermatology, Bd. 87, Nr. 4: S. 815-824
Paller, Amy S.; Beck, Lisa A.; Blauvelt, Andrew; Siegfried, Elaine C.; Cork, Michael J.; Wollenberg, Andreas; Chen, Zhen; Khokhar, Faisal A.; Vakil, Jignesh; Zhang, Annie; Bansal, Ashish und Cyr, Sonya L.
(2022):
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
In: Pediatric Dermatology, Bd. 39, Nr. 2: S. 187-196
Gottlieb, Alice B.; Blauvelt, Andrew; Prinz, Jörg C.; Papanastasiou, Philemon; Pathan, Rashidkhan; Nyirady, Judit; Fox, Todd und Papavassilis, Charis
(2016):
Secukinumab Self-Administration by Prefilled Syringe Maintains. Reduction of Plaque Psoriasis Severity Over 52 Weeks: Results of the FEATURE Trial.
In: Journal of Drugs in Dermatology, Bd. 15, Nr. 10: S. 1226-1234